| Drug / Therapy | zidesamtinib |
| Indication | ROS1+ NSCLC |
| Decision Type | PDUFA |
| Conditions | ROS1+ NSCLC |
| Interventions | zidesamtinib |
Nuvalent Inc (NUVL) operates in the Oncology sector. The current BTS Score is 57 (Grade: C).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for zidesamtinib by Nuvalent Inc (NUVL) is scheduled for June 30, 2026. This is the target date for the FDA to make a decision on this application.
zidesamtinib is being developed by Nuvalent Inc for the treatment of ROS1+ NSCLC. It is under FDA review.
If zidesamtinib receives FDA approval, Nuvalent Inc (NUVL) would be able to market the drug in the United States for ROS1+ NSCLC. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for NUVL on DilutionWatch at dilutionwatch.com/stock/NUVL.html.
You can view the full BiotechSigns company profile for Nuvalent Inc (NUVL) at biotechsign.com/app/company/NUVL, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.